Overview

Glulisine Pre- and Postmeal

Status:
Completed

Trial end date:
2002-03-01

Target enrollment:

Participant gender:

Summary

To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal

Phase:

Phase 1

Details

Lead Sponsor:

Sanofi

Treatments:

Insulin
Insulin glulisine
Insulin, Globin Zinc